Title: A New Current of Biomarkers Research in Gynecologic Cancer
Handling Editor: Yoshihiro Kikuchi
President, Ooki Memorial Kikuchi Cancer Institue forWomen, Saitama, Japan
Contact: [email protected]
Biomarkers Journal is very important Journal to improve and progress precision medicine especially in cancer treatment. New findings regarding drugs affecting signal transduction pathways and immune checkpoit blockers have been accumulated. Through these analyses, we have learned better findings for cancer treatment. I expect such new biomarkers paving the ways to new treatment strategies resulting in precision medicine and any other biomarkers being useful for early diagnosis and treatment sensitivity.
Yoshihiro Kikuchi, MD, PhD
Biomarkers Journal is an open access journal and publish the manuscripts after thorough peer review. Biomarkers are referred to measurable indicator of some biologic condition or severity of disease state. They are useful in a number of ways, including measuring the progress of disease, evaluating the most effective therapeutic regimens. They are divided into different types based on their characteristics, known as Imaging biomarkers, Diagnostic biomarkers, Molecular biomarkers etc. Some of them are also used in pharma industry as to know the drug optimization in drug development. This journal seeks high quality of journals related to new research of biomarkers and their usage in different fields.
Open access journal is an innovative platform, in which all articles are published online with rapid review process and anyone in the global can access it with free of charge.
The main aim of this journal is to create the scientific environment on biomarkers research to authors, readers and upcoming scientists to share their views. Provide the platform for anyone in global to get to know the latest updates on biomarkers research and as well where these can be used.
Submit manuscript at http://www.editorialmanager.com/imedpubjournals/ or send as an e-mail attachment to the Editorial Office at [email protected]/ [email protected]
Cancer Markers are made by normal cells as well as by tumor cells. These are the substances that are produced by cancer or by other cells of the body in response to cancer or certain begin conditions. These substances can be found in the blood, urine, stool, tumour tissue, or other tissues or bodily fluids of some patients with cancer
Related Journals of Cancer Biomarkers
Journal Cancer Biomarkers, Journal of Molecular Biomarkers & Diagnosis, Journal of Biomarkers in Cancer, Biomarker Journals, Cancer Diagnostic and Predictive Biomarker
Proteomic approaches to the identification of disease biomarkers rely principally on the comparative analysis of protein expression in normal and disease tissues to identify aberrantly expressed proteins that may represent new biomarkers, analysis of secreted proteins (in cell lines and primary cultures), and direct serum protein profiling. Proteomics methodologies include assessment of protein expression (by Western blotting and enzyme-linked immunosorbent assay and by other antibody-based methods) and the isolation, identification, and quantification of proteins in biosamples with high-resolution 2-dimensional gel electrophoresis, high-performance liquid chromatography, surface chromatography by adsorption of proteins to activated surfaces (matrix-assisted laser desorption–ionization technology), or via peptide ionization procedures and mass spectroscopy.
Related Journals of Proteomic Biomarkers
Journal of Proteomics, Journal of Proteomics & Bioinformatics, Journal of Proteomics, Journal of proteome research,Proteome Science, International Journal of Proteomics, Clinical Proteomics.
Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events and optimizing drug dose. Drug labeling may contain information on genomic biomarkers and can describe:
Drug exposure and clinical response variability.
Risk for adverse events.
Mechanisms of drug action.
Polymorphic drug target and disposition genes.
Related Journals of Pharmacogenomic Biomarkers
Journal of Pharmacogenomics & Pharmacoproteomics, Journal of Disease Markers.
DNA biomarkers are also important in many research and clinical applications. The field of DNA-based biomarkers has benefited greatly from the rapidly changing landscape of DNA sequencing technologies and the wealth of data produced. Here, RNA analysis can confirm and complement DNA analysis in many applications and research areas.
Related Journals of DNA Biomarkers
Advancements in Genetic Engineering, Cloning & Transgenesis, Transcriptomics: Open Access, Gene Technology, Journal of DNA Research, Journal of DNA Repair, Journal of DNA and Cell Biology, Journal of Mobile DNA.
Any biochemical compound such as an antigen, antibody, abnormal enzyme, or hormone that is sufficiently altered in a disease to serve as an aid in diagnosing or in predicting susceptibility to the disease.
Related Journals of Biochemical Markers
The International Journal of Biological Markers, Biochemical and Biophysical Research, Biochemical Genetics, Biochemical Journal, Biochemical Pharmacology.
A biological indicator that signals a changed physiological state, stress, or injury due to disease or the environment, for example, an elevated serum level of prostate-specific antigen is a biomarker for prostate cancer.
Related Journals of Molecular Biomarkers
Journal of Molecular Biomarkers & Diagnosis, Journal of Genetic Testing and Molecular Biomarkers, Journal of Molecular Biomarkers Diagnosis, Journal of Current Biomarker Findings.
Pharmacodynamic Biomarkers can provide information on the pharmacologic effects of a drug on its target. Pharmacodynamic biomarkers studies may provide insights into proof of mechanism (i.e., Does the agent hit its intended target?) and proof of concept (i.e., Does hitting the drug target result in the desired biologic effect?). Pharmacodynamic biomarkers studies may also provide information on the optimal biologic dosing or scheduling of a targeted agent.
A Pharmacodynamic Biomarkers can be used to examine the link between drug regimen, target effect, and biological tumor response. Coupling new drug development with focused PD biomarker measurements provides critical data to make informed, early go/no-go decisions, to select rational combinations of targeted agents, and to optimize schedules of combination drug regimens. Use of PD endpoints also enhances the rationality and hypothesis-testing power throughout drug development, from selection of lead compounds in preclinical models to first-in-human trials. Given these critical roles in delivering targeted therapy, the introduction of validated and reliable clinical PD assays is warranted in drug development.
Related Journals of Pharmacodynamic Biomarkers
Journal of Bioequivalence & Bioavailability, Clinical & Experimental Pharmacology, Journal of Cancer Biomarkers, Journal of Circulating Biomarkers, The Open Biomarkers Journal, Journal of Advanced Biomarkers Research, Jacobs Journal of Biomarkers, Journal of Biomarkers in Medicine.
Metabolomics is the latest of the omics technologies that employs state of the art analytical instrumentation in conjunction with pattern recognition techniques to monitor and discover metabolic changes in subjects related to disease status or in response to a medical or external intervention. Metabolomics is increasingly being applied towards the identification of biomarkers for disease diagnosis, prognosis and risk prediction.
Related Journals of Metabolomic Biomarkers
Journal of Metabolomics and Systems Biology, Journal of Metabolomics, Journal of Metabolites, International Journal of Metabolomics and Systems Biology Research.
Cytogenetic Biomarkers in peripheral blood lymphocytes such as chromosomal aberrations, sister chromatid exchanges and micronuclei have long been applied in surveillance of human genotoxic exposure and early effects of genotoxic carcinogens. The use of these biomarker assays is based on the fact that most established human carcinogens are genotoxic in short-term tests and capable of inducing chromosomal damage.
Related Journals of Cytogenic Biomarkers
Cytogenetic and Genome Research, Molecular Cytogenetics, Cytogenetic and Genome Research.
The term “Biomarkers” refers to a specific kind of biological indication (or marker) of a disorder. So, autism biomarkers could be related to a behavior or genetic event or brain signature that is specific to autism. By looking for biomarkers, we really hope to be able to identify signs of autism as early as possible. Autism is a developmental disorder, so by intervening during early development, we hope to give each infant or child the opportunity to develop and improve skills (e.g., attention, cognition, social interactions) for long-term positive outcomes.
Related Journals of Autism Biomarkers
Autism-Open Access, Journal of Communication Disorders, Deaf Studies & Hearing Aids, Journal of Child and Adolescent Behaviour, Journal of Psychological Abnormalities in Children, Autism Research and Treatment, Journal of Autism Research, Autism Research Journal, Journal of Autism, Journal of Autism and Developmental Disorders, Focus on Autism and Other Developmental Disabilities, Good Autism Practice, Journal of Autism and Developmental Disorders, Molecular Autism, Research in Autism Spectrum Disorders.
A biomarker refers to a measurable indicator of some biological state or condition and can exist in the form of DNA, RNA, protein or other molecules. With the advent of transcriptomic technologies such as microarrays and next-gen RNA sequencing, RNA biomarkers have grown exponentially and hold great promise for a wide range of research and clinical applications. At ACD, we offer researchers a reliable platform for in situ RNA biomarker analysis using a wide range of sample types including routine formalin-fixed paraffin-embedded tissue.
RNA expression reflects the state of a biological system. RNA expression levels are highly dynamic and integrate both genetic and epigenetic mechanisms of gene regulation. Therefore, RNAs serve as an effective “phenotype” of the functional state of the cell.
Measuring RNA biomarkers as RNA provides the most direct route for biomarker validation and assay development. Most biomarkers discovered today are RNA from transcriptomic studies. One significant bottleneck in advancing RNA biomarker discoveries to the clinic has been the lack of standardized and robust technologies for measuring RNA biomarkers in situ in clinical specimens. Translating RNA biomarkers into protein biomarkers for in situ analysis faces a host of issues such as poor correlation between RNA and Protein, antibody quality or availability, significant time and resource requirement of new antibody development and validation, or simply lack of protein counterparts in the case of noncoding RNAs. ACD’s RNA scope assay technology overcomes these pitfalls and provides a direct path from discovery to clinical assays by maintaining the biomarkers at the RNA level.
Related Journals of RNA Biomarkers
RNA Journal, Journal of Non-Coding RNA, Journal of Nucleic Acids Research,Journal of DNA and RNA Research.
Inflammation is not just something that affects the joints and connective tissues of the body. Recent studies have linked inflammation of the arteries to heart attack and stroke. While there are four major risk factors that may contribute to an increased risk of heart related illness or event, as many as 50% of all cases do not present with these classic markers. In these cases, doctors are linking inflammation of the arteries to the, sometimes, fatal effects of heart attack and stroke. Inflammatory markers are too non-specific to be a useful tool for diagnosing serious underlying disease and should rarely be used in this situation.
Related Journals of Inflammatory Markers
Journal of Inflammatory Bowel Diseases & Disorders, Research & Reviews: Journal of Inflammation, Journal of Inflammation, Journal of Inflammatory markers, Journal of Mediators of Inflammation.
Genomic biomarkers are variants in the DNA code that alone or in combination are associated with disease susceptibility, disease expression, and disease outcome, including therapeutic responses. Single nucleotide polymorphisms (SNPs; DNA sequence variation when a single nucleotide in the genome sequence is altered) have been evaluated extensively in relation to CVD. The 2 classic complementary approaches used for relating genetic sequence variation to CVD risk are the linkage approach and the association strategy.
Related Journals of Genomic Biomarkers
Journal of Genomics, International Journal of Genomics, Journal of Genetics and Genomics, Journals International Genomic Medicine.
The term behavioral markers refers to a prescribed set of behaviors indicative of some aspect of performance. Typical behaviors are listed in relation to component skills and are now used for selection, training, and competence assessment in professions such as anesthesiology.
Related Journals of Behavioral Markers
Journal of Behavioral Education, Behavioural Processes, Physiology & Behavior, Journal of Behavioral Health.
Biomarkers research in bipolar disorder is a new field with an expanding knowledge. Bipolar disorder is associated with an imbalance of diverse biological systems, including immune system, neurotrophins, neuroendocrine axis and oxidative stress. Peripheral molecules related to the pathophysiological mechanisms underlying bipolar disorder may be putative biomarkers of the disease. Bipolar disorder is associated with structural and functional neuroimaging changes associated with brain atrophy, notably involving the enlargement of lateral ventricles and decrease in prefrontal cortex and amygdala volumes. Bipolar disorder peripheral and neuroimaging findings may reflect neuroprogressive processes of the illness. A single candidate biomarker seems unlikely to tap clinical and biological heterogeneity of bipolar disorder.
Related Journals of Biomarkers for Bipolar Disorder
Journal of Psychiatry, Brain Disorders & Therapy, Bipolar Disorder: Open Access, International Journal of Bipolar Disorders, Bipolar Disorders Journal.
Author(s): Matthew Schmitz, Angela Gambelunghe, Youngliang Li, Giacomo Muzi, Angela Giuliani and Paul Brandt-Rauf
Author(s): Marta A, Carolina T, Ulises U, Lionel G, Jose D, Marco C, Monica C, Alcides Z, Hugo B,Pedro M and Veronica RM
Author(s): Ikpotokin Samuel Osahon
All Published work is licensed under a Creative Commons Attribution 4.0 International License
Copyright © 2017 All rights reserved. iMedPub Last revised : November 24, 2017